- Home
- Free App Analytics
- AntiCoagAF
- AntiCoagAF Vs. dark GCS
AntiCoagAF vs dark GCS Usage & Stats
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban.
Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information.
Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.
- Apple App Store
- Paid
- Medical
Store Rank
- -
The Glasgow Coma Scale (GCS) was developed in 1974 to assess the depth of impaired consciousness and coma following trauma. There have been a few tweaks to the GCS over the past 40 years as well as some clarification in testing.
Also includes pediatric GCS (for ages 2 and younger).
- Apple App Store
- Paid
- Medical
Store Rank
- -
AntiCoagAF vs. dark GCS ranking comparison
Compare AntiCoagAF ranking trend in the past 28 days vs. dark GCS
Rank
No Data Available
AntiCoagAF vs. dark GCS ranking by country comparison
Compare AntiCoagAF ranking trend in the past 28 days vs. dark GCS
All categories
No Data Available
Medical
Compare to any site with our free trial
AntiCoagAF VS.
dark GCS
December 31, 2024